{
  "id": 7839620,
  "title": "Cellares and GenomeFrontier Therapeutics Partner to Advance Automated Manufacturing of GF-CART01",
  "url": "https://urgent.news/2026/09/16/cellares-and-genomefrontier-therapeutics-partner-to-advance-automated",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-16T18:04:09.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/bioprocessing/cellares-and-genomefrontier-therapeutics-partner-to-advance-automated-manufacturing-of-gf-cart01/"
  },
  "original_language": "en",
  "account": "Cellares, an integrated development and manufacturing organization, has teamed up with GenomeFrontier Therapeutics, a Taiwanese cell therapy company focused on virus-free CAR T therapies, to explore automated manufacturing for GF-CART01, GenomeFrontier's investigational CAR T-cell therapy. The partnership aims to evaluate the translation of GenomeFrontier's manufacturing process to Cellares' Cell Shuttle platform, with a focus on supporting transfection unit operations using Cellares' integrated electroporator. This marks Cellares' first development collaboration in Asia and aligns with GenomeFrontier's U.S. clinical initiative for GF-CART01, which is being developed for B-cell malignancies, including several types of lymphoma. GenomeFrontier's CEO, Sareina Wu, emphasized the importance of an automated manufacturing strategy that supports both clinical development and future scale, given the increasing complexity of next-generation cell therapy manufacturing. Fabian Gerlinghaus, co-founder and CEO of Cellares, highlighted the Cell Shuttle's capability to automate complex processes, such as electroporation-based workflows, ensuring scalability and reliability throughout clinical development. The collaboration aims to address the challenges of labor-intensive, variable, and difficult-to-scale autologous CAR T manufacturing, ultimately improving manufacturing reliability and patient access.",
  "summary": "The partnership marks Cellares’ first collaboration with a cell therapy developer in Asia and will evaluate automated manufacturing of GenomeFrontier’s virus-free CAR T process for clinical manufacturing in the U.S. The post Cellares and GenomeFrontier Therapeutics Partner to Advance Automated Manufacturing of GF-CART01 appeared first on GEN - Genetic Engineering and Biotechnology News .",
  "key_points": [
    "Cellares partners with GenomeFrontier Therapeutics to advance automated manufacturing of GF-CART01.",
    "Aim is to improve manufacturing reliability and patient access for B-cell malignancies."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}